Autologous peripheral blood stem cell transplantation (PBSCT) for Hodgkin lymphoma (HL) is curative for many patients with relapsed or refractory disease. Relapsing disease, however, remains a major problem. Neoplastic transformation of B-lymphocytes probably underlies the development of classical HL. Whether clonal B cells are critical for disease evolution and response to therapy in HL remains uncertain. We investigated the impact of clonal B cells detected in peripheral blood stem cell (PBSC) collections on the outcome of patients with HL undergoing transplant. Qualitative semi-nested PCR was carried out on genomic DNA from mononuclear cells from PBSCs to determine the presence of clonal immunoglobulin heavy chain (IgH) complementary-determining region 3 (CDR3) gene rearrangements. Clinical factors were assessed for their association with relapse, overall survival (OS) and progression-free survival (PFS). Among 39 patients undergoing PBSCT, 12 grafts (31%) were PCR positive for clonal IgH rearrangements. OS was better in the PCRnegative group (logrank test, P ¼ 0.041). The OS at 5 years was 81% in PCR-negative versus 39% in PCR-positive patients; hazard ratio was 3.23 (95% confidence interval: 0.98-10.63). There was a trend towards better PFS (logrank test, P ¼ 0.12), estimated as 71% at 5 years in PCR-negative versus 41% in PCR-positive patients. Clonal B-lymphocytes in PBSC collections of patients with HL identify patients at risk of poor outcome. Larger series are needed to confirm our observations. Insight regarding the role of monoclonal B cells may lead to improved therapies.
Introduction
Autologous peripheral blood stem cell transplantation (PBSCT) is curative for many patients with relapsed or refractory classical Hodgkin lymphoma (HL). [1] [2] [3] [4] However, up to 50% cases will relapse and insight regarding risk factors for subsequent disease progression is needed. The Reed-Sternberg (RS) cells in HL are probably derived from germinal centre B-lymphocytes, suggested by detection of clonal immunoglobulin heavy chain gene (IgH) rearrangements in microdissected single RS cells. 5 Subpopulations of B cells expressing CD40L and CD30L found at the sites of tumour involvement may also be important for the survival of RS cells, and for the maintenance and propagation of disease. 6 The importance of B cells in HL, therefore, provides the rationale to evaluate peripheral blood stem cell (PBSC) collections for the presence of dominant B cell populations that may influence transplantation outcomes.
RS cells have not been previously detected in PBSC collections and analysis of grafts for tumour cells or critical accessory cells is not routinely carried out in HL. RS cells were not detected by PCR with immunoglobulin specific primers in the PBSC collection of one patient. 7 An RS cell line, however, was created from peripheral blood mononuclear cells of a patient with HL and bone marrow involvement, suggesting that RS cells can circulate. 8 In this study, we tested mononuclear cells from PBSCs of HL patients undergoing autologous PBSCT for the presence of clonal B cell populations. We hypothesized that the detection of clonal B cell populations in PBSCs from patients with HL using sensitive molecular methods may identify patients at an increased risk of relapse and death. The impact of monoclonal IgH rearrangements was examined and compared with established prognostic factors with regard to progression free survival (PFS) and overall survival (OS).
Materials and methods

Patients
Patients undergoing autologous PBSCT at The Ottawa Hospital for classical HL between April 2000 and January 2006 were included; those undergoing a second transplant were excluded. A comparison group for the molecular testing consisted of patients without B cell lymphomas undergoing autologous PBSCT for testicular cancer, T cell lymphoma, Wilm's tumour or neuroblastoma during the same period. Patients provided informed consent for the use of medical information and analysis of PBSC cells for research purposes in accordance with the institutional research ethics board. All patients whose PBSC collections were analysed and who underwent autologous PBSCT were included.
Molecular analysis for clonal B cell populations
To assess for the presence of clonal B cell populations, mononuclear cell genomic DNA from PBSC collections was subjected to semi-nested PCR of the third immunoglobulin heavy chain complementary determining region (IgH CDR3). Genomic DNA (200 mg) was extracted from mononuclear cells using a QIAmp DNA Blood Mini Kit (Qiagen, Mississauga, Canada). Aliquots of 0.5 mg of genomic DNA were amplified for 29 cycles using 0.4 mM of VHFR3 and 0.4 mM of LJH primers described previously. 9 A second round of PCR was carried out on a 1:40 volume of the first PCR product using 0.4 mM VHFR3 and 0.4 mM VLJH primers. The second PCR was also run for 29 cycles using Taq DNA polymerase. Products from the second round of PCR were separated by electrophoresis in 8% polyacrylamide gel impregnated with ethidium bromide and visualized under ultraviolet light. Patients who underwent collection on consecutive days had two or more PCR assays carried out. The pooled PBSC graft was deemed positive if any of the PCR amplifications yielded a dominant band, consistent with a monoclonal IgH rearrangement. A polyclonal smear of PCR amplification products indicated the absence of a dominant monoclonal B cell population ( Figure 1) . A sensitivity analysis was carried out using DNA extracted from a clonal B cell line obtained from InviviScribe Technologies (San Diego, CA, USA). A 10-fold dilution series was created using 1 mg of monoclonal DNA diluted in mononuclear cell DNA obtained from healthy donors. Monoclonal B cells were detected up to and including the 1:100 000 dilution ( Figure 1 ). The results of PCR amplification were not communicated to the treating team and did not form part of the hospital medical record.
Analysis of prognostic indicators
Disease characteristics of prognostic value were obtained from the Transplant Program Database at The Ottawa Hospital and from review of hospital records. The definitions that follow were adopted for categorization of prognostic indicators. Histological subtype was assigned according to the original pathology report at diagnosis. If subsequent biopsies reported a different histological subtype they were classified as 'other'. Stage of disease, presence of bulk and extranodal involvement were determined by radiographic review at transplant and by review of pathology reports, and were verified by two of the authors. Bulk was defined as tumour exceeding 10 cm in maximal dimension. Time to first relapse was calculated from date of diagnosis to the first radiographic scan indicating increase in abnormal node size, new organ involvement or development of new lesions. Primary refractory disease was defined as progressive or stable disease while receiving first-line chemotherapy. Chemosensitive disease required partial or complete radiological response after completion of first-line chemotherapy. Patients with no marrow involvement included patients with no disease on marrow examination and patients with normal blood counts who did not undergo marrow biopsy. Logrank analysis was carried out to identify the importance of clonal IgH rearrangements in predicting PFS and OS. Cox regression analysis was then carried out to determine the impact on progression and survival after adjusting for other prognostic factors. Potential prognostic variables included (a) Ann Arbour stage (I-II vs III-IV), (b) presence or absence of bulky disease at diagnosis, (c) extranodal involvement at diagnosis, (d) time to first relapse after initial therapy (o12 months vs 412 months), (e) marrow involvement at diagnosis, (f) primary refractory disease vs relapsed disease, (g) optimal graft CD34 þ count (o5.0 Â 10 6 per kg vs X5.0 Â 10 6 per kg), and (h) the presence or absence of monoclonal IgH rearrangement in the graft. Hasenclever scores could not be determined for all patients and were not used.
Analysis of overall and progression-free survival Survival and time to progression after PBSCT were determined from the day of PBSC infusion. Progression occurred if radiographic studies indicated an increase in abnormal node size, new organ involvement or development of new lesions. Patients were assessed with CT scans 1-4 times annually and examined in clinic every 4-6 months or as necessary. Patients outside the Ottawa area were followed similarly by their community specialist at a similar frequency. Medical records from outside facilities were requested in all cases and information was included in the determination of relapse and survival. Overall survival and progression free survival estimates were determined according to the method of Kaplan and Meier. 10 
Results
Patient characteristics
The PBSC collections from a total of 39 patients with HL were subjected to molecular analysis for the presence of monoclonal B cell populations. Of these, 12 (31%) had clonal IgH gene rearrangements detected in at least one collection, whereas 27 (69%) were PCR negative. Only two patients required more than one PBSC collection. In one, both products were negative for IgH rearrangements; in the second, only one collection was positive. This patient was categorized as PCR positive. PBSC samples from a second group of 15 patients transplanted at our centre over a similar time period with T cell lymphoma (5 patients), testicular cancer (7 patients) and other solid tumours (3 patients) were all negative. The cohort of patients with HL was analysed further in terms of risk factors for disease progression after PBSCT, including histological subtype, stage of disease, bone marrow or extranodal involvement and the presence of bulky disease. No significant differences in these risk factors were observed between the group with monoclonal IgH rearrangements and the group without (see Table 1 ).
Analysis of progression free and overall survival
The median follow-up for all patients was 3.2 years (range, 0.1-7.2 years) and was not different between the two groups (Wilcoxon signed rank test: P-value ¼ 0.27). Disease recurred in 6 patients with grafts containing clonal B cells (50%). Five had progression of HL, three of which were confirmed by repeat biopsy. One additional patient developed B cell lymphoma. Relapse was detected in 7 patients among those with PCR-negative grafts (26%, P ¼ 0.16) and confirmed using biopsies in two patients. There was a trend towards shorter time to progression in the PCR-positive group, which was not statistically significant (250 vs 341 days following transplant, P ¼ 0.62). PFS was not significantly different between the two groups (P ¼ 0.12 by logrank test, see Figure 2 ), but was 71% at 5 years for the PCR-negative group and only 41% for those with PCR-positive collections. The hazard ratio for progression in patients with clonal IgH rearrangements was 2.3 (95% confidence interval, 0.78-6.9).
A total of 11 patients died (28%) during the follow-up period, including 5 with PCR-negative and 6 with PCR positive grafts. OS was different between the two groups (P ¼ 0.041 by log rank test, see Figure 3 ) and was 81% at 5 years in the PCR negative and 39% in the PCR positive group. The unadjusted hazard ratio for death was 3.23 (95% confidence interval, 0.98-10.63) in patients with clonal IgH rearrangements. Transplant-related non-relapse mortality accounted for 8% of the total deaths and included 1 (8%) patient with a PCR-positive graft and 2 (7%) patients with PCR-negative PBSCs. All other deaths (5 with PCR-positive graft and 3 with PCR-negative graft) were attributed to progressive disease.
Analysis of prognostic variables in predicting PFS and OS
After adjusting for prognostic factors considered in our study (see Table 2 ), Cox regression analysis revealed that positive IgH PCR results were associated with a hazard ratio of 3.63 for OS (95% confidence interval, 0.56-23.5) and 3.17 for PFS (0.62-17.37). None of the covariates included in our model revealed significant adjusted hazard ratios.
Discussion
Our results suggest that monoclonal B-lymphocytes detected in PBSC grafts in classical HL are associated with worse prognosis. Clonal IgH rearrangements in PBSCs were associated with worse OS on the basis of logrank analysis. The relatively small numbers of patients in each patient group precluded meaningful multivariate analysis, although the magnitude of hazard ratios for PFS and OS are suggestive of a possible important association. With greater follow-up and larger studies, the impact of IgH clonal status on outcome may be confirmed. Although we did not observe a statistical difference in PFS, we suspect that the trend towards longer time to progression in the PCR-negative group contributed towards the observed difference in OS if fewer patients with progressive disease in this group died as a result of their relapse. We accept that with longer follow-up, the association with survival observed in our study may not persist without including more patients. Insight regarding the etiology and biological role of the monoclonal B cells, however, may emerge as an important avenue of investigation to allow the development of improved treatment strategies for these patients. Monoclonal B cells detected in PBSC grafts are unlikely to represent malignant Hodgkin or RS cells in our view as only a small number of patients had known disease in the marrow before transplantation. Verification of this assumption by isolation and analysis of B cells as well as CD30 þ RS cells was not technically possible with the available pathological material from this cohort. RS cells with identical immunoglobulin rearrangements have been detected in affected tissues during the course of disease in several reports, showing the clonality of HL. 7, 11, 12 Messenger RNA transcripts of the IgH locus are absent and surface immune globulins cannot be detected on RS cells, suggesting a role for transcriptional repression or the presence of defective immunoglobulin genes. 12 The use of sensitive molecular methods at the time of diagnosis to evaluate for the presence of clonal B cell populations in the marrow or in lymph node tissue has not been reported and may provide additional insight regarding the relevance of these B cell populations in HL. Mononclonal B cells have been previously recognized as precursors of lymphoproliferative malignancies. Monoclonal gammopathy of undetermined significance evolves to overt haematological malignancy at a rate of 0.4-1.0% annually. 13, 14 In a recent study, the presence of monoclonal gammopathy was associated with reduced survival, regardless of transformation to malignancy.
14 Recently, analysis of HL cells lines suggests that small circulating B cells are precursors to RS cells. 15 In our study, we may be observing the persistence of pre-malignant B cell clones in the PBSC grafts of patients with a worse prognosis. Whether these cells can be linked to the development of HL in vivo remains to be determined.
Inflammatory cells, including B-and T-lymphocytes infiltrate lymph nodes and affected organs in HL, causing the bulk of detectable disease. Whether oligoclonal B cell populations are present, which provide an essential growth advantage to the Hodgkin or RS cells remains under investigation. Interestingly, the use of anti-CD20 þ antibodies alone 16 or in combination with chemotherapy 17 has yielded favourable responses in some patients with classical HL, irrespective of the CD20 status of malignant RS cells, perhaps through modulation of serum interleukin-6 levels elaborated by infiltrating B cells. 16 Specific tumour antigens can evoke B cell responses in some tumours and the role of viral antigens in the development of HL has long been postulated. Epstein-Barr virus latent membrane protein-1, Bcl-2, Bax and CD20 have all been implicated in classical HL and may have prognostic relevance. [18] [19] [20] [21] The monoclonal bands detected by PCR varied in molecular size between patients, suggesting heterogeneity in the specificity of the clonal B cell populations. Analysis of IgH rearrangements for tumour and viral antigen specificity was not carried out in our study.
The emergence of clonal B cell populations occurs in some patients with autoimmune disease and may reflect a degree of immune dysregulation. Autoimmunity was associated with an increased risk of developing HL in one population-based study. 22 In patients with autoimmune disease, monoclonal B cell populations have been detected and antibodies may be specific for target antigens implicated in the evolution of disease, 23, 24 but may also be associated with immune dysregulation. 25 The lack of molecular markers of RS cells has precluded the investigation of minimal residual disease in HL. Abnormal cells with morphological characteristics and immunophenotype similar to RS cells have been identified in apheresis products of patients with HL. 26 Post hoc analysis of survival in patients who received PBSCs containing these RS-like cells has revealed no significant difference. Detection of clonal B cells, however, has not been systematically examined in HL patients and the effect of manipulating PBSC grafts to eliminate B cells or purge tumour cells has not been investigated in HL to the best of our knowledge.
We explored the potential role of additional clinical factors that may be associated with PFS and OS. We were not able to include all elements of accepted prognostic scoring systems such as the Hasenclever index. 27 We are not aware of any studies that have validated a specific scoring system for patients before transplantation. Several of the factors that we examined, however, have been previously identified as prognostic factors for patients before transplantation 28 and none of these factors seemed as strongly associated with outcome as monoclonal IgH rearrangement status.
The results of our study suggest that the detection of clonal B lymphocytes in autologous PBSCs by sensitive molecular methods may be associated with an increased risk of relapse and mortality after transplantation in patients with classical HL. Routine use of PCR to detect clonal IgH rearrangements cannot be recommended on the basis of our results but could be considered further in investigational studies by transplant centres to identify patients at increased risk of poor outcome. Further insight regarding the role of clonal B cells in these patients may allow the development of new strategies to improve outcomes for these patients.
